Poly (ADP-Ribose) polymerase inhibitors (PARPI): Associated thrombosis in patients with ovarian cancer

被引：0
作者：
Sanchez Canovas, M. [1 ]
Lopez Robles, J. [1 ]
Garcia Verdejo, F. J. [2 ]
Cacho Lavin, D. [3 ]
Guirao, S. [4 ]
Garrido Fernandez, A. [5 ]
Coma Salvans, E. [6 ]
Quintanar Verduguez, T. [7 ]
Salvador Coloma, C. [8 ]
Fernandez Garay, D. [9 ]
Cumplido, J. D. [10 ]
Ferrer Perez, A. I. [11 ]
Carbo Bague, A. [12 ]
Teigell Munoz, F. J. [13 ]
Munoz Martin, A. J. [14 ]
机构：
[1] Hosp Gen Univ Morales Meseguer, Med Oncol Dept, Murcia, Spain
[2] Hosp Univ Jaen, Med Oncol Dept, Jaen, Spain
[3] HUMV Hosp Univ Marques de Valdecilla, Med Oncol, Santander, Spain
[4] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain
[5] Hosp Univ Alvaro Cunqueiro, Med Oncol Dept, Pontevedra, Spain
[6] Hosp Duran & Reynals, ICO Inst Catala Oncol lHospitalet, Med Oncol Dept, Lhospitalet De Llobregat, Spain
[7] Hosp Gen Univ Elche, Med Oncol Dept, Alicante, Spain
[8] Hosp Lluis Alcanyis Xativa, Med Oncol Dept, Valencia, Spain
[9] Hosp Costa del Sol, Agencia Sanitaria Costa del Sol, Med Oncol Dept, Marbella, Spain
[10] Hosp Univ Torrevieja, Med Oncol Dept, Torrevieja, Spain
[11] Obispo Polanco Hosp, Med Oncol Dept, Teruel, Spain
[12] ICO Girona Inst Catala Oncol Girona, Med Oncol Dept, Girona, Spain
[13] Hosp Univ Infanta Cristina, Internal Med Dept, Parla, Spain
[14] Hosp Gen Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1955
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1861P
引用
收藏
页码：S1095 / S1095
页数：1
相关论文
共 50 条
  • [31] Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer
    Zheng, Feiyue
    Zhang, Yi
    Chen, Shuang
    Weng, Xiang
    Rao, Yuefeng
    Fang, Hongmei
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 123
  • [32] Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
    Xu, Qin
    Li, Zhengyu
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [33] Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
    Boussios, Stergios
    Moschetta, Michele
    Karihtala, Peeter
    Samartzis, Eleftherios P.
    Sheriff, Matin
    Pappas-Gogos, George
    Ozturk, Mehmet Akif
    Uccello, Mario
    Karathanasi, Afroditi
    Tringos, Michail
    Rassy, Elie
    Pavlidis, Nicholas
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (24)
  • [34] Clinicopathologic and genomic characteristics of patients with advanced ovarian, breast, and prostate cancer treated with poly (ADP-ribose) polymerase inhibitors (PARPi) in a real-world setting
    Velimirovic, Marko
    Kuzmanovic, Teodora
    Nikoo, Maedeh Zokaei
    Brihn, Lesil
    Konig, Vicky
    Watson, Tejuana
    Austin, Teana
    Bokovitz, Lauren
    Behera, Tapas Ranjan
    Savage, Gabriel
    Kilbane, Megan
    Azzato, Elizabeth M.
    Tu, Zheng Jin
    Ma, Wen Wee
    Vargas, Roberto
    Miller, Jacob
    Yilmaz, Emrullah
    Ni, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective
    Sandhu, Shahneen K.
    Yap, Timothy A.
    de Bono, Johann S.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (01) : 9 - 20
  • [36] Mechanisms of resistance to poly (ADP-ribose) polymerase inhibitors in prostate cancer
    Atiq, Mohammad
    Chakraborty, Goutam
    Nandakumar, Subhiksha
    Mazzu, Ying Z.
    Stopsack, Konrad
    Yoshikawa, Yuki
    Khan, Nabeela
    Lee, Gwo-Shu Mary
    Kantoff, Philip W.
    CANCER RESEARCH, 2019, 79 (13)
  • [37] The Evolution of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer
    Domchek, Susan M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (05) : 330 - 332
  • [38] Potential biomarkers of Poly (ADP-ribose) polymerase inhibitors for cancer therapy
    Zhou, Haiyan
    Hu, Bailong
    Li, Wei
    Huang, Niwen
    Wei, Bo
    Mo, Xiangang
    Zhang, Bei
    Wang, Yiming
    Liu, Xingde
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (05): : 4446 - 4453
  • [39] PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy
    Chelariu-Raicu, Anca
    Trillsch, Fabian
    Burges, Alexander
    Czogalla, Bastian
    Hester, Anna
    Wuerstlein, Rahel
    Harbeck, Nadia
    Mahner, Sven
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (05) : 812 - 822
  • [40] STRUCTURAL REQUIREMENTS FOR INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE
    SESTILI, P
    SPADONI, G
    BALSAMINI, C
    SCOVASSI, I
    CATTABENI, F
    DURANTI, E
    CANTONI, O
    HIGGINS, D
    THOMSON, C
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1990, 116 (06) : 615 - 622
12345